Skip to content
Screener

Immunovant, Inc. IMVT Switzerland — Total loss before income taxes

Other geography segments

United States
$100.99M+670%
United Kingdom
-$55K
Bermuda
-$39K+61.0%

Similar metrics at other companies

Roivant Sciences logo
ROIVSwitzerland — Total (loss) income from continuing operations before income taxes
542,775,000%+278,123,885pp
Garmin logo
GRMNNon Switzerland — Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
$153.35M+42.1%
Mirion Technologies logo
MIRForeign — Income (loss) before income taxes
$11.98M+26.4%
Q2 Holdings logo
QTWOU.S. — Income (loss) before income taxes
$11.57M+220%
Thor Industries logo
THOTotal North America — INCOME (LOSS) BEFORE INCOME TAXES:
$78.03M-40.2%
Indivior Pharmaceuticals, Inc. logo
INDVReportable Segment — Total income (loss) before income taxes
$115M+94.9%

Other financials

Income statement

See full
Net income-$147.9M-38.9%
EPS (diluted)-$0.73-15.9%

Balance sheet

See full
Cash & equivalents$902.1M+26.4%
Total debt$72.0K-26.5%
Total equity$852.6M+20.5%
Total assets$957.0M+23.3%

Cash flow

See full
Operating cash flow-$95.1M+14.1%
CapEx$8.0K-96.0%
Free cash flow-$95.1M+14.2%

Valuation

See full
Market cap$8.21B+201%
Enterprise value$7.31B+89.7%

Returns & leverage

See full
Return on equity-64.8%+2.5pp
Debt / equity0.0×
Current ratio9.1×-2.1×

Where this comes from

Reported directly by Immunovant, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.

The source filing: Immunovant, Inc.’s 10-K, filed May 20, 2026.

Filed
May 20, 2026, 7:28 AM EDT
Fiscal year
FY2026
Accession
0001764013-26-000064
Line itemYears Ended March 31, 2026Years Ended March 31, 2025Years Ended March 31, 2024
(Loss) income before income taxes
United States$100,991$(17,730)$(16,180)
Switzerland(606,288)(395,119)(242,518)
Bermuda(39)(100)(71)
United Kingdom(55)
Total loss before income taxes$(505,391)$(412,949)$(258,769)
Current taxes
United States – Federal$880$562

Item 8. Financial Statements and Supplementary Data

FAQ

What is Immunovant, Inc.'s switzerland — total loss before income taxes?
Immunovant, Inc. (IMVT) reported switzerland — total loss before income taxes of -$151.57M in Q1 2026.
How has Immunovant, Inc.'s switzerland — total loss before income taxes changed year-over-year?
Immunovant, Inc.'s switzerland — total loss before income taxes decreased by 53.4% year-over-year, from -$98.78M to -$151.57M.
What is the long-term trend for Immunovant, Inc.'s switzerland — total loss before income taxes?
Over 4 years (2022 to 2026), Immunovant, Inc.'s switzerland — total loss before income taxes has grown at a 52.3% compound annual growth rate (CAGR), from -$112.79M to -$606.29M.
What does switzerland — total loss before income taxes mean?
This metric represents the pre-tax financial loss generated by operations within the Switzerland geographic segment. It reflects the net impact of segment-specific revenues and operating expenses before accounting for income tax provisions. Monitoring this figure helps investors assess the burn rate and operational efficiency of the company's Swiss-based activities.

Ask your AI about Immunovant, Inc.'s switzerland — total loss before income taxes.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude